Vaccine via the nasal passage could be the new line of defence against Strep A

As Streptococcus A cases continue to be prevalent, a new nasal vaccine could provide long-term protection from the deadly bacteria. The development of a Strep A vaccine which is currently in Phase 1 clinical trials in Canada and quickly advancing to Phase 2 efficacy trials.

As Streptococcus A cases continue to be prevalent, a new nasal vaccine could provide long-term protection from the deadly bacteria. The development of a Strep A vaccine which is currently in Phase 1 clinical trials in Canada and quickly advancing to Phase 2 efficacy trials.

Read more https://www.sciencedaily.com/releases/2023/10/231004201931.htm